Table 2.
RAASi therapy at initiation of SZC
| All patients (N = 589) | Optimized RAASia (N = 456) | Did not optimize RAASib (N = 133) | p value | |
|---|---|---|---|---|
| RASi | 556 (94.4%) | 430 (94.3%) | 126 (94.7%) | 1.00 |
| ACEi | 301 (51.1%) | 232 (50.9%) | 69 (51.9%) | 0.92 |
| ARB | 249 (42.3%) | 195 (42.8%) | 54 (40.6%) | 0.73 |
| ARNI | 19 (3.2%) | 15 (3.3%) | 4 (3.0%) | 1.00 |
| DRI | 1 (0.2%) | 1 (0.2%) | 0 (0.0%) | 1.00 |
| MRA | 70 (11.9%) | 56 (12.3%) | 14 (10.5%) | 0.69 |
Patients could be taking monotherapy or combination therapy so the percentages may not add to 100%
ACEi angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blocker; ARNI angiotensin receptor neprilysin inhibitor; DRI direct renin inhibitor; MRA mineralocorticoid receptor antagonist, RAASi renin-angiotensin-aldosterone system inhibitor; RASi renin-angiotensin system inhibitor
aOptimized RAASi included patients with the same dose or with an up-titration
bNon-optimized RAASi included patients who discontinued or with a down-titration